BridgeMD
SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS
EU CTIS ID: 2024-516372-14-00
What this study is testing
The main objective of the study is to demonstrate that prophylactic treatment of patients with asymptomatic frequent (>10%) PVCs is superior to simple follow‐up strategy with no therapy to prevent subsequent LV dysfunction at 24 months. The prophylactic treatment is based on drugs ± ablation (ablation can be performed if the PVC burden remain>10% after 2 lines of AAD treatment since the initiation of the study).
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18 ≤ Age ≤ 85
- PVC burden ≥ to 10% regardless of current or preexisting antiarrhythmic drug intake (for instance, a patient under betablocker therapy because of his PVCs or hypertension can be included)
- Asymptomatic status
- Normal (>or= 55%) LVEF. Patients with underlying cardiomyopathy can be included as long as LV function remains preserved.
- Signed informed consent
You likely can't join if
- Pregnant woman or Female of childbearing potential without effective method of birth control or nursing woman
- Patients that can’t undergo MRI study
- De novo requirement for antiarrhythmic drug prescription for another indication (e.g. atrial fibrillation…)
- The physician already decided that the patient requires drug initiation or escalation;
- Ischemic cardiomyopathy requiring revascularization (PCI or surgery)
- History of LV dysfunction
See the full eligibility criteria
- 18 ≤ Age ≤ 85
- PVC burden ≥ to 10% regardless of current or preexisting antiarrhythmic drug intake (for instance, a patient under betablocker therapy because of his PVCs or hypertension can be included)
- Asymptomatic status
- Normal (>or= 55%) LVEF. Patients with underlying cardiomyopathy can be included as long as LV function remains preserved.
- Signed informed consent
- Pregnant woman or Female of childbearing potential without effective method of birth control or nursing woman
- Patients that can’t undergo MRI study
- De novo requirement for antiarrhythmic drug prescription for another indication (e.g. atrial fibrillation…)
- The physician already decided that the patient requires drug initiation or escalation;
- Ischemic cardiomyopathy requiring revascularization (PCI or surgery)
- History of LV dysfunction
- Participation in another research involving the human person
- Patient under legal protection
- Non affiliation to a social security scheme
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.